Funding for this research was provided by:
Received: 19 July 2022
Accepted: 23 May 2023
First Online: 13 June 2023
: All methods were carried out in accordance with relevant guidelines and regulations. The protocol for this study was reviewed and approved by the Japanese Pharmaceuticals and Medical Devices Agency and this post-marketing surveillance was conducted in accordance with Good Post-marketing Study Practice according to ordinance by the Japanese Ministry of Health, Labour, and Welfare (MHLW Ordinance No. 171 in 2004: Ministerial Ordinance for Good Post-Marketing Surveillance and Clinical Studies, available from: ExternalRef removed), which does not specify requirement of ethical approval or informed consent (all data included in this study were anonymous), for observational studies of this type. All study participating institutes have confirmed permission to include the anonymized data in this study and publication. The authors thank the patients and all the investigators for their participation.
: Not applicable.
: HM has received personal fees from Sanofi during the conduct of the study. NM has received personal fees from Janssen, AstraZeneca, and Sanofi; and grants from Janssen, AstraZeneca, Bayer, Roche, NSD, Astellas Pharma, Taiho, Amgen, Eisai, Lilly, Pfizer, Chugai, and PRA Health Science. KS has received personal fees from Bayer Yakuhin, AstraZeneca, Janssen, Ono Pharmaceutical Co., Ltd., MSD, Merck, Astellas Pharma, Takeda, Daiichi Sankyo Co., Ltd., Chugai Pharma, and Nippon Shinyaku; and research grants from Astellas Pharma, Takeda, Daiichi Sankyo Co., Ltd., Chugai Pharma, Nippon Shinyaku, Sanofi, and Kyowa Kirin. HK, TS, and YS are employees of Sanofi. HK and YS hold stocks in Sanofi.